Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

151.13 -1.37 (-0.90%)
Streaming Delayed Price Updated: 10:15 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
News headline image
Should You Buy Gilead Sciences Before Feb. 10? ↗
Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue? 
Via The Motley Fool
News headline image
Exploring Gilead Sciences&#39;s Earnings Expectations ↗
 
Via Benzinga
News headline image
Gilead Sciences (GILD) Reports Q4: Everything You Need To Know Ahead Of Earnings
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday afternoon. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Inc. (NASDAQ:GILD) Passes the Caviar Cruise Quality Investing Screen ↗
Via Chartmill
GILEAD SCIENCES INC (NASDAQ:GILD): A High-Yield, Low-Payout Dividend Stock for Disciplined Investors ↗
Via Chartmill
News headline image
Here&#39;s How Much You Would Have Made Owning Gilead Sciences Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
This Overlooked Biotech Giant Could Surprise Investors This Quarter
Investors may be underestimating the long-term potential of Gilead’s evolving portfolio. 
Via Barchart.com
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Challenges
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide
Via PRLog
News headline image
Large Cap Biopharmaceuticals: A Core Position For A Healthcare Portfolio ↗
Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer yielding 6%, the sector remains a key volatility hedge following... 
Via Talk Markets
Topics Stocks
News headline image
3 Cash-Producing Stocks with Warning Signs
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
The Commonwealth Club Honors Black History Month With Event Featuring Top Black Leaders in AI & Biopharma Discussing the Future of Healthcare
Via Get News
Topics Artificial Intelligence
News headline image
Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?
Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Demystifying Gilead Sciences: Insights From 17 Analyst Reviews ↗
 
Via Benzinga
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Here&#39;s How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Earnings Preview: What to Expect
Gilead Sciences is expected to release its fiscal fourth-quarter earnings soon, and analysts project a decline in EPS. 
Via Barchart.com
Topics Artificial Intelligence ETFs Government
News headline image
Looking Into Gilead Sciences Inc&#39;s Recent Short Interest ↗
 
Via Benzinga
News headline image
A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)
Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage... 
Via PredictStreet
Topics Economy Initial Public Offering
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings?
Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 10.1%. 
Via StockStory
Topics Stocks
News headline image
U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗
Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations. 
Via Stocktwits
Topics Government
News headline image
3 Cash-Flow Machines Investors May Want Heading Into 2026 ↗
Via MarketBeat
News headline image
Here&#39;s How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value
As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.